Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury
AUTOR(ES)
Pachori, Alok S.
FONTE
National Academy of Sciences
RESUMO
Ischemia and reperfusion represent major mechanisms of tissue injury and organ failure. The timing of administration and the duration of action limit current treatment approaches using pharmacological agents. In this study, we have successfully developed a preemptive strategy for tissue protection using an adenoassociated vector system containing erythropoietin hypoxia response elements for ischemia-regulated expression of the therapeutic gene human heme-oxygenase-1 (hHO-1). We demonstrate that a single administration of this vector several weeks in advance of ischemia/reperfusion injury to multiple tissues such as heart, liver, and skeletal muscle yields rapid and timely induction of hHO-1 during ischemia that resulted in dramatic reduction in tissue damage. In addition, overexpression of therapeutic transgene prevented long-term pathological tissue remodeling and normalized tissue function. Application of this regulatable system using an endogenous physiological stimulus for expression of a therapeutic gene may be a feasible strategy for protecting tissues at risk of ischemia/reperfusion injury.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=514470Documentos Relacionados
- The Role of Sympathetic System as a Therapeutic Option in the Ischemia/Reperfusion Injury
- Interleukin 1 pretreatment decreases ischemia/reperfusion injury.
- von Willebrand factor, exercise, and ischemia/reperfusion injury.
- PKCβ regulates ischemia/reperfusion injury in the lung
- Role of sarcolemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice
